-
Linogliride fumarate
- names:
(E)-N-((E)-1-methylpyrrolidin-2-ylidene)-N'-phenylmorpholine-4-carboximidamide fumarate
- CAS号:
78782-47-5
MDL Number: - MF(分子式): C20H26N4O5 MW(分子量): 402.45
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | Linogliride fumarate |
| 英文别名 | Linogliride fumarate; McN-3935; McN 3935; McN3935; |
| CAS号 | 78782-47-5 |
| Inchi | InChI=1S/C16H22N4O.C4H4O4/c1-19-9-5-8-15(19)18-16(20-10-12-21-13-11-20)17-14-6-3-2-4-7-14;5-3(6)1-2-4(7)8/h2-4,6-7H,5,8-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b17-16-,18-15+;2-1+ |
| InchiKey | ZSAMTXUUUFXIII-CZKNSKRSSA-N |
| 分子式 Formula | C20H26N4O5 |
| 分子量 Molecular Weight | 402.45 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Linogliride fumarate(CAS:78782-47-5):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Linogliride fumarate is an antidiabetic agent. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Levin PA, Jovanovic L, Chalew SA, Martin L, Pitarra DK, Kim F, Kowarski AA. Linogliride fumarate, representing a new class of oral hypoglycemic agent for diabetes. Clin Pharmacol Ther. 1987 Nov;42(5):498-503. PubMed PMID: 3315390. |
| [2]Ronner P, Cheong E, Khalid P, Tuman RW, Matschinsky FM. Effect of linogliride on hormone release from perfused rat pancreas. Fuel dependence and desensitization by tolbutamide. Diabetes. 1991 Jul;40(7):878-84. PubMed PMID: 2060724. |
| [3] Ronner P, Higgins TJ, Kimmich GA. Inhibition of ATP-sensitive K+ channels in pancreatic beta-cells by nonsulfonylurea drug linogliride. Diabetes. 1991 Jul;40(7):885-92. PubMed PMID: 2060725. |
| [4] Salhanick AI, Leighty SJ, Amatruda JM. Postreceptor regulation of insulin action in primary cultures of rat hepatocytes by oral hypoglycemic agents: effects of linogliride and chlorpropamide. Horm Metab Res. 1989 Nov;21(11):596-601. PubMed PMID: 2687145. |
| [5] Wu WN, Mutter MS. Biotransformation of linogliride, a hypoglycemic agent in laboratory animals and humans. J Pharm Biomed Anal. 1995 Jun;13(7):857-67. PubMed PMID: 8562609. |
6: Zawalich WS, Rasmussen G, Tuman RW, Tutwiler GF. Influence of the oral hypoglycemic agent linogliride (McN-3935) on insulin secretion from isolated rat islets of Langerhans. Endocrinology. 1987 Mar;120(3):880-5. PubMed PMID: 3542516.7: Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS. Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol. 1995 Feb;162(2):163-71. PubMed PMID: 7822427.8: Ng KT, Holland ML, Plutte JA. Determination of linogliride in biological fluids by high-performance liquid chromatography. J Chromatogr. 1984 Nov 28;311(2):418-23. PubMed PMID: 6520190.9: Klimatcheva E, Wonderlin WF. An ATP-sensitive K(+) current that regulates progression through early G1 phase of the cell cycle in MCF-7 human breast cancer cells. J Membr Biol. 1999 Sep 1;171(1):35-46. PubMed PMID: 10485992.10: Chrzanowski FA, Ahmad K. The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release. Drug Dev Ind Pharm. 2017 Mar;43(3):421-431. doi: 10.1080/03639045.2016.1257019. Epub 2016 Nov 21. PubMed PMID: 27808569.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


